Splenomegaly is a marker of disease progression1
Larger baseline spleen volume is associated with increased risk of death2
- 14% increase in risk of death for each additional 500 cm3 of spleen volume at baseline (HR=1.14; 95% CI: 0.61-1.36; P=0.64)1
- More than 80% of patients with MF experience splenomegaly3,4
Splenomegaly worsens with or without conventional therapies5
Spleen volume increases in the BAT group mirrored those observed with placebo5

Adapted from: Mesa RA et al. Haematologica. 2014;99(2):292-298.5
- Complications associated with splenomegaly include portal hypertension and variceal bleeding6,7
- In clinical trials, patients treated with best available therapy (BAT) had increases in spleen size that were similar to those who received placebo5
- BAT included any single treatment or combination of treatments (such as hydroxyurea [47%], glucocorticoids [16%], or no drug treatment [33%])5
Learn about significant spleen reduction with JAKAVI from COMFORT-II Splenomegaly is a debilitating manifestation that contributes to high disease burden and is an important factor to consider when managing MF, regardless of patient prognostic risk categorisation5,8